Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + oxaliplatin in relapsed or refractory pediatric solid tumors
NL-OMON29764Phase 2Active, not recruiting
- Sponsor
- Gustave Roussy
- Start
- Apr 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine and oxaliplatin in Nonhematologic neoplasms, neuroblastoma, osteosarcoma (OS) and 2 more, sponsored by Gustave Roussy. Started Apr 2007; status: active, not recruiting.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
Nonhematologic neoplasmsneuroblastomaosteosarcoma (OS)medulloblastomabrain neoplasm
Beyond the preview
Go deeper on NL-OMON29764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29764.